Dynamics of Adipokine and Cytokine Profiles as Predictors of Hepatic Recovery After Myocardial Revascularization in Comorbid Metabolic Fatty Liver Disease
Keywords:
Keywords: adiponectin, leptin, ghrelin, IL-6, TNF-α, CABG, MAFLD, systemic inflammation, ademetionine.Abstract
Relevance. Adipose tissue is a biologically active endocrine organ secreting adipokines that regulate metabolism and inflammation: adiponectin (insulin-sensitizing and anti-inflammatory), leptin (a pro-inflammatory mediator) and ghrelin (with cardio- and hepatoprotective potential) [1, 2]. In MAFLD, reduced adiponectin and ghrelin together with elevated leptin promote hepatic steatosis, inflammation and fibrosis while potentiating cardiovascular risk [1, 3]. CABG triggers a potent systemic inflammatory response through cardiopulmonary bypass [4]; whether this response is amplified and prolonged in MAFLD patients and contributes to post-operative hepatic deterioration remains insufficiently studied.
References
1.Machado MV, Coutinho J, Carepa F, Costa A, Proença H, Cortez-Pinto H. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2012;24(10):1166–1172.
2.Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062–1079.
3.Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–e185.
4.Squiccimarro E, Stasi A, Lorusso R, Paparella D. Narrative review of the systemic inflammatory reaction to cardiac surgery and cardiopulmonary bypass. Artif Organs. 2022;46(4):568–577.
5.Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281.
6.Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470.
7.Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097–1109.
8.Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015;10(3):e0122124.